PHASE-I STUDY OF RECOMBINANT HUMAN INTERFERON-BETA IN PATIENTS WITH ADVANCED CANCER

  • 1 April 1987
    • journal article
    • research article
    • Vol. 6  (2) , 121-129
Abstract
Twenty-two patients with advanced cancer were entered into a phase I study of recombinant human interferon beta (IFN-.beta.). The maximum tolerated dose was 100 .times. 106 IU administered intravenously on a three times weekly schedule, and persistent fever was the dose-limiting toxicity. The majority of patients tolerated administration of IFN-.beta. well with negligible hematologic toxicity. Details of the clinical effects of escalating doses of recombinant human IFN-.beta., administered three times weekly, are described.